LABT — Lakewood-Amedex Biotherapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2079272 ·
Last close
$0.21
Market Cap
$508.3K
52W High
$98.20
52W Low
$0.17
ADV30
30,183,962
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,789,660 | -3,772,008 | 4,960,009 | 2,584,774 | 628,926 |
| Mar 2026 | 0 | — | -886,750 | -923,291 | 196,343 | 11,709 | 3,037,991 |
| Dec 2025 | 0 | — | -712,060 | -744,918 | 481,598 | 236,400 | 2,446,135 |
| Sep 2025 | 0 | — | -1,880,317 | -1,907,159 | 985,118 | 658,410 | 2,251,434 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,485,776
Investing CF
$0
Financing CF
$6,802,095
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-7.77
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-68,639,996
Inventory
—
Receivables
$4,526
ST Investments
$2,000,000
EBIT TTM
$-7,222,908
Pretax Income TTM
$-7,347,376
Interest Exp TTM
$124,468
Analysts
2
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,772,370 | -3,847,637 | 481,598 | 2,446,135 | -1,964,537 | -1,944,698 |
| Dec 2024 | 0 | -4,026,820 | -4,855,405 | 1,070,581 | 660,970 | 409,611 | -5,723,322 |
| Dec 2023 | 0 | -8,636,719 | -8,281,960 | 6,893,904 | 2,335,577 | 4,558,327 | -6,816,114 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$4,960,009
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VBIO | Valion Bio, Inc. | $482.3K | $0.54 | — |
| EVFM | Evofem Biosciences, Inc. | $569.9K | $0.00 | — |
| BIOM | BIOMOLECULAR LIFE HOLDINGS, INC. | $580.8K | $0.50 | — |
| CYTOF | Altamira Therapeutics Ltd. | $405.8K | $0.07 | — |
| PTIX | Protagenic Therapeutics, Inc.\new | $814.6K | $0.45 | — |
News headlines (Yahoo Finance, 1h cache)
Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption
2026-11-05 15:46 · Yahoo
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
2026-10-21 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
2026-10-07 12:02 · Yahoo
Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections
2026-09-28 16:26 · Yahoo
Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates
2026-09-28 14:57 · Yahoo
LABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers
2026-09-28 12:16 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
2026-09-28 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
2026-09-24 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
2026-09-21 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
2026-09-18 12:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.